The FDA has posted notices for two nationwide dietary supplement recalls involving products found to contain undeclared pharmaceutical ingredients.
New York found widespread safety violations in med spas, and FDA inspectors cited a Texas distributor for violating the DSCSA.
Our analysis of data in September and October 2025 revealed that large-scale freight fraud involving GLP-1s, oncology drugs, and other high-demand pharmaceuticals continues unabated.
CBP reported seizing 450 shipments of illegally imported contact lenses and prescription medicines. Dozens of state AGs asked Meta to enforce policies against misleading weight loss products.
The med spa owner admitted to using unapproved injectables that sickened at least 10 patients. New York authorities announced the results of a 2024 crackdown on illegal med spas. PSM published in The Journal of Illicit Trade, Financial Crime, and Compliance.
PSM wrote the House Energy & Commerce Committee in support of the Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act, to help protect the American drug supply from unsafely compounded medication.
FDA announced the seizure of dozens of counterfeit Ozempic 1mg injection pens labeled with an authentic lot number, PAR1229, but displaying the expiration and lot numbers for the product in the wrong place.
The FDA and Novo Nordisk are warning the public about counterfeit Ozempic injections circulating in the legitimate U.S. drug supply chain. The FDA announced the seizure of multiple batches of counterfeit Ozempic 1 mg injections, labeled with lot number PAR1229, on December 5, 2025. Their contents and safety are unverified and pose serious health risks.
MMWR field notes about Americans hospitalized after self-injecting imported Botox raise serious concerns about patient safety.
Surveys document consumer behaviors when purchasing medication from online pharmacies, finding that the public may not be aware of the dangers of IOPs.